CTY
INSIDER BUYCity Therapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
PositiveCity Therapeutics successfully closed a $230M IPO in mid-October 2026 and initiated its first Phase 1 trial for CITY-RBP4 (Stargardt disease) in November, establishing itself as a newly public RNAi-focused biotech. Analyst coverage initiation has been broadly bullish with average 12-month price target of $33, though the stock has traded below IPO pricing despite positive momentum, reflecting typical post-IPO volatility and the inherent risk profile of early-stage clinical programs.
Red flags
- •Early-stage biotech with no approved products or clinical data yet — all value is speculative
- •Stock trading below IPO price (~$18–19 range) despite bullish analyst initiations suggests market skepticism or profit-taking
- •Limited public operating history; no earnings reports or revenue to evaluate financial performance
- •Single Phase 1 program disclosed; pipeline concentration risk if lead candidates face clinical setbacks
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Viking Global | SC 13G | NEW | 7.0% | -5.3% vs SPY -11.7% abs | 2026-10-26 | ↗ |